SILVER SPRING, Md., Feb. 21, 2012 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that the U.S. Food and Drug Administration has accepted for review the new drug application (NDA) for...
14 Feb 2012
United Therapeutics Corporation Reports 2011 Fourth Quarter and Annual Financial Results
SILVER SPRING, Md., Feb. 14, 2012 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the fourth quarter and year ended December 31, 2011."I am pleased that we met our...
SILVER SPRING, Md., Feb. 7, 2012 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will release its fourth quarter and annual 2011 financial results before market open on Tuesday...
SILVER SPRING, Md., Feb. 6, 2012 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced receipt of a Paragraph IV Certification Notice Letter on February 3, 2012 from Sandoz Inc. (Sandoz) advising...
SILVER SPRING, Md. and CHERTSEY, England, Dec. 27, 2011 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) and its wholly-owned subsidiary, United Therapeutics Europe, Ltd., announced today that the French...
SILVER SPRING, Md., Oct. 27, 2011 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the third quarter ended September 30, 2011."We achieved over $200 million in...
SILVER SPRING, Md., Oct. 20, 2011 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will release its third quarter 2011 financial results before market open on Thursday, October 27...
SILVER SPRING, Md., Oct. 12, 2011 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) (the "Company") today announced the pricing of its previously announced offering of $210 million aggregate principal amount...
SILVER SPRING, Md., Oct. 11, 2011 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) (the "Company") today announced that it intends to offer, subject to market and other conditions, $210 million aggregate...
SILVER SPRING, Md., Oct. 10, 2011 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced that its subsidiary, Unither Virology, LLC, has been awarded a contract for up to approximately $45 million under...
24 Aug 2011
FREEDOM-C(2) Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Does Not Meet Primary Endpoint
SILVER SPRING, Md., Aug. 24, 2011 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today the completion of its FREEDOM-C(2) Phase 3 trial of treprostinil diethanolamine (oral treprostinil), an...
SILVER SPRING, Md., July 28, 2011 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the quarter ended June 30, 2011."I'm pleased with the successful unblinding of...